Cargando…

Immune-related arthritis following pelvic radiation therapy in a patient with lung cancer receiving long-term immune checkpoint blocker treatment: Case report

Radiotherapy can trigger immune-related out-of-field “abscopal” response. We report a patient with advanced NSCLC (non-small cell lung cancer) receiving long-term anti-PD1 (programmed cell death protein 1) who have developed out-of-field immune-related arthritis following pelvic irradiation.

Detalles Bibliográficos
Autores principales:	Aldea, Mihaela, Belkhir, Rakiba, Colomba, Emeline, Blanchard, Pierre, Danlos, Francois-Xavier, Botticella, Angela, Terlizzi, Mario, Deutsch, Eric, Le Péchoux, Cecile, Planchard, David, Michot, Jean-Marie, Besse, Benjamin, Levy, Antonin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637658/ https://www.ncbi.nlm.nih.gov/pubmed/36353627 http://dx.doi.org/10.3389/fimmu.2022.920130

Ejemplares similares

Stereotactic body radiotherapy for extra-cranial oligoprogressive or oligorecurrent small-cell lung cancer()
por: Levy, Antonin, et al.
Publicado: (2023)

Neutrophilia as prognostic biomarker in locally advanced stage III lung cancer
por: Schernberg, Antoine, et al.
Publicado: (2018)

Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience
por: Botticella, Angela, et al.
Publicado: (2019)

Meningeal “Lazarus Response” to Lorlatinib in a ROS1-Positive NSCLC Patient Progressing to Entrectinib
por: Facchinetti, Francesco, et al.
Publicado: (2021)

Biomarkers for immune checkpoint blockers
por: Wienand, Kirsty, et al.
Publicado: (2018)

Thoracic radiotherapy in small cell lung cancer—a narrative review
por: Levy, Antonin, et al.
Publicado: (2021)

Immune Checkpoint Blockers and Ovarian Cancer
por: Bose, Chinmoy K
Publicado: (2017)

Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients
por: Boros, Angela, et al.
Publicado: (2017)

Tumour motion management in lung cancer: a narrative review
por: Botticella, Angela, et al.
Publicado: (2021)

Toward Systems Biomarkers of Response to Immune Checkpoint Blockers
por: Lapuente-Santana, Óscar, et al.
Publicado: (2020)

A Highlight of the Mechanisms of Immune Checkpoint Blocker Resistance
por: Huang, Qian, et al.
Publicado: (2020)

Prognostic Value of the Lung Immune Prognosis Index Score for Patients Treated with Immune Checkpoint Inhibitors for Advanced or Metastatic Urinary Tract Carcinoma
por: Parent, Pauline, et al.
Publicado: (2023)

The efficacy of immune checkpoint inhibitors in thoracic malignancies
por: Remon, Jordi, et al.
Publicado: (2021)

Supramolecular prodrug hydrogelator as an immune booster for checkpoint blocker–based immunotherapy
por: Wang, Feihu, et al.
Publicado: (2020)

Cross-Reactivity and Functionality of Approved Human Immune Checkpoint Blockers in Dogs
por: Pantelyushin, Stanislav, et al.
Publicado: (2021)

Perspectives of traditional Chinese medicine to patch up immune checkpoint blockers
por: Tsao, Shiu Ying
Publicado: (2022)

Oxazaphosphorines combined with immune checkpoint blockers: dose-dependent tuning between immune and cytotoxic effects
por: Delahousse, Julia, et al.
Publicado: (2020)

Editorial: Cellular and Molecular Mechanisms of Immune Checkpoint Blockers in Anti-leukemia/Lymphoma Immune Therapy
por: Ganjalikhani-Hakemi, Mazdak, et al.
Publicado: (2022)

A Case of Acute Heart Failure due to Immune Checkpoint Blocker Nivolumab
por: Sharma, Munish, et al.
Publicado: (2019)

Increased abscopal responses after radiation therapy for oligoprogressive patients receiving immune checkpoint inhibitors?
por: Doyen, Jérôme, et al.
Publicado: (2023)

Mesenchymal traits at the convergence of tumor-intrinsic and -extrinsic mechanisms of resistance to immune checkpoint blockers
por: Trono, Paola, et al.
Publicado: (2017)

Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors
por: Wu, Y. Linda, et al.
Publicado: (2023)

(18)F-FDG PET and DCE kinetic modeling and their correlations in primary NSCLC: first voxel-wise correlative analysis of human simultaneous [18F]FDG PET-MRI data
por: Besson, Florent L., et al.
Publicado: (2020)

Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors
por: De Martin, Eleonora, et al.
Publicado: (2020)

Targeting TMEM176B Enhances Antitumor Immunity and Augments the Efficacy of Immune Checkpoint Blockers by Unleashing Inflammasome Activation
por: Segovia, Mercedes, et al.
Publicado: (2019)

Value of a Signature of Immune-Related Genes in Predicting the Prognosis of Melanoma and Its Responses to Immune Checkpoint Blocker Therapies
por: Yuan, Bo, et al.
Publicado: (2022)

Complete Remission After Immunotherapy-Induced Abdominal Tuberculosis in a Patient With Advanced NSCLC Treated With Pembrolizumab: A Case Report
por: Riudavets, Mariona, et al.
Publicado: (2022)

Losartan controls immune checkpoint blocker-induced edema and improves survival in glioblastoma mouse models
por: Datta, Meenal, et al.
Publicado: (2023)

Immune checkpoint inhibitors in elderly patients treated for a lung cancer: a narrative review
por: Naltet, Charles, et al.
Publicado: (2021)

Retracted: Value of a Signature of Immune-Related Genes in Predicting the Prognosis of Melanoma and Its Responses to Immune Checkpoint Blocker Therapies
por: Methods in Medicine, Computational and Mathematical
Publicado: (2023)

Study and analysis of antitumor resistance mechanism of PD1/PD‐L1 immune checkpoint blocker
por: Wang, Zhengyi, et al.
Publicado: (2020)

PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models
por: Yamazaki, Takahiro, et al.
Publicado: (2020)

Withaferin A Increases the Effectiveness of Immune Checkpoint Blocker for the Treatment of Non-Small Cell Lung Cancer
por: Khalil, Roukiah, et al.
Publicado: (2023)

Brain Radiation Necrosis: Current Management With a Focus on Non-small Cell Lung Cancer Patients
por: Loganadane, Gokoulakrichenane, et al.
Publicado: (2018)

Correlation of the TIGIT-PVR immune checkpoint axis with clinicopathological features in triple-negative breast cancer
por: Boissière-Michot, Florence, et al.
Publicado: (2022)

Longitudinally Extensive Myelitis Associated With Immune Checkpoint Inhibitors
por: Picca, Alberto, et al.
Publicado: (2021)

LMAP-07 POTENTIAL MECHANISM OF IMMUNE ESCAPE RELATED TO TUMOR-ASSOCIATED MACROPHAGE IN GLIOBLASTOMA AFTER COMBINED THERAPY WITH RADIOTHERAPY AND IMMUNE CHECKPOINT BLOCKER
por: Zhang, Chi, et al.
Publicado: (2023)

A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers
por: Gettinger, S. N., et al.
Publicado: (2018)

Y(90)-radioembolisation in hepatocellular carcinoma induces immune responses calling for early treatment with multiple checkpoint blockers
por: Rivoltini, Licia, et al.
Publicado: (2023)

Metastatic Renal Medullary and Collecting Duct Carcinoma in the Era of Antiangiogenic and Immune Checkpoint Inhibitors: A Multicentric Retrospective Study
por: Guillaume, Zoé, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_11hqc7kiaae7lgocei6ttd1mba